Search clinical trials for: complement dose

Total 23285 results

BioCryst Pharmaceuticals

Recruiting

Dose Escalation of BCX10013 in Subjects With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

South Africa, Malaysia
CSL Behring

Recruiting

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Complement Deficiencies

Australia
Fujian Medical University Union Hospital

Recruiting

Efficacy, Safety and Response Predictors of Adjuvant Astragalus for Cognition in Orthostatic Hypotension

Alzheimer Disease | Orthostatic Hypotension

China
Indiana University
The National Center for Complementary and Integrative Health

Recruiting

Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus

Kidney Disease, Chronic | CBD | Transplant Complication

United States
Kira Pharmacenticals (US), LLC.

Not yet recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104

Paroxysmal Nocturnal Hemoglobinuria

China
Pharvaris Netherlands B.V.

Recruiting

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (RAPIDe-2)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

United States, Bulgaria, Czechia, Hungary, Spain, France, Germany, Poland, Canada, Israel
The University of Queensland
Chinese University of Hong Kong; University of Malaya; The Alfred; Centre Hospitalier... and other collaborators

Recruiting

PNEUmonia DOSing in Critically Ill Patients (PNEUDOS) (PNEUDOS)

Pneumonia

Hong Kong, France, Belgium, Australia, Malaysia
Yale University
National Center for Complementary and Integrative Health (NCCIH)

Recruiting

CBD-Microglia PET Study

Healthy | CBD

United States
Novartis Pharmaceuticals

Completed

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

Taiwan, Singapore, Korea, Republic of, Malaysia
Alexion Pharmaceuticals, Inc.
Celerion

Completed

Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants

Healthy

United Kingdom
St. Jude Children's Research Hospital
Children's Hospital of Philadelphia; National Heart, Lung, and Blood Institute... and other collaborators

Active, not recruiting

Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B

Hemophilia B

United States, United Kingdom
BioMarin Pharmaceutical

Active, not recruiting

A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema (HAErmony-1)

Hereditary Angioedema | HAE

Spain, United States, Australia
BioCryst Pharmaceuticals

Active, not recruiting

Berotralstat Treatment in Children With Hereditary Angioedema (APeX-P)

Hereditary Angioedema | Pediatric

Spain, Austria, Canada, France, Germany, Israel, Italy, Poland, Romania, United Kingdom
Pharvaris Netherlands B.V.

Active, not recruiting

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II (HAE CHAPTER-1)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

United States, Poland, Germany, Austria, Bulgaria, Canada, Ireland, Italy, United Kingdom
Alexion Pharmaceuticals, Inc.

Completed

A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants

Healthy

United Kingdom
Beth Israel Deaconess Medical Center
National Center for Complementary and Integrative Health (NCCIH)

Completed

Effects of Open-label vs Double-blind Treatment in IBS

Irritable Bowel Syndrome | Placebo Effect | Placebos | Peppermint Oil

United States
National Institute of Allergy and Infectious Diseases...
National Institutes of Health (NIH); Department of Health and Human Services

Active, not recruiting

Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b Adjuvanted With 3M-052-AF + Alum in Healthy, HIV-1 Uninfected Adult Participants

HIV-1-infection

United States
KalVista Pharmaceuticals, Ltd.

Terminated

A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II (KVD824-201)

Angioedema, Hereditary, Types I and II

United States, Czechia, Germany, Hungary, Italy, North Macedonia, United Kingdom, Australia, Bulgaria, Canada, France, New Zealand, Puerto Rico
Emory University
National Center for Complementary and Integrative Health (NCCIH); Children's...

Completed

Arginine Therapy for Sickle Cell Disease Pain

Sickle Cell Disease | Vaso-occlusive Pain Episode

United States
Amgen

Completed

A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants

Electrocardiography

United States
Myovant Sciences GmbH

Completed

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

Endometriosis

United States, Spain, Argentina, Belgium, Bulgaria, Canada, Czechia, Finland, Hungary, Poland, Portugal, South Africa, Ukraine, Australia, Brazil, Chile, Italy, New Zealand, Romania, Georgia
Pharvaris Netherlands B.V.

Completed

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (RAPIDe-1)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

Bulgaria, United States, Spain, Israel, Germany, Canada, Czechia, France, Hungary, Italy, Netherlands, Poland, United Kingdom
Alexion

Completed

A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants

Healthy

United Kingdom
Alexion

Completed

A Study of a Single Dose of ALXN1210 in Healthy Participants

Healthy

Canada
Alexion

Completed

A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants

Healthy

United Kingdom
NYU Langone Health
Dyax Corp.

Withdrawn

Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema

Hereditary Angioedema Types I and II

United States
Kira Pharmacenticals (US), LLC.

Completed

To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104

Paroxysmal Nocturnal Hemoglobinuria

Australia
Galenika AD Beograd
Medicinsko društvo za racionalnu terapiju Republike Srbije (MEDRAT)

Completed

Treatment of Resistant Hypertension: Cohort Study (TRYCORT)

Resistant Hypertension

Serbia
Arbor Pharmaceuticals, Inc.

Completed

An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

Hypertension

United States, Brazil, Turkey, Poland, Mexico, Colombia, Italy, Argentina, Bulgaria, Hungary, South Africa, Ukraine
Alexion Pharmaceuticals

Completed

Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab

Paroxysmal Nocturnal Hemoglobinuria

United Kingdom
Alexion Pharmaceuticals

Completed

Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria | PNH

Korea, Republic of, Canada, France, Germany, Spain, Taiwan, United Kingdom
Vital Pakistan Trust
Aga Khan University

Active, not recruiting

Nutritional Support and Prophylaxis Doses of Azithromycin for Pregnant Women - Mumta Pregnant Women Trial (MumtaPW)

Undernutrition

Pakistan
InflaRx GmbH
Iqvia Pty Ltd

Terminated

Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA

Granulomatosis With Polyangiitis (GPA) | Microscopic Polyangiitis (MPA)

United States, Canada
Alexion Pharmaceuticals

Completed

Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PNH

Korea, Republic of, Australia
Myovant Sciences GmbH

Completed

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Uterine Fibroid | Heavy Menstrual Bleeding

United States, Belgium, Czechia, South Africa, Chile, Brazil, Hungary, Poland
Myovant Sciences GmbH

Completed

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Uterine Fibroid | Heavy Menstrual Bleeding

United States, Italy, Poland, Brazil, South Africa, United Kingdom
University of Maryland, Baltimore
Chinese University of Hong Kong; National Center for Complementary and Integrative...

Completed

Dose Escalation Trial of Traditional Chinese Medicine for Irritable Bowel Syndrome (TCM- IBS) (TCM-IBS)

Irritable Bowel Syndrome

Hong Kong
Washington University School of Medicine

Completed

Assessing the Dose Response of a Lead Fiber Snack Prototype (FDR)

Microbiota | Gastrointestinal Microbiome

United States
KalVista Pharmaceuticals, Ltd.

Completed

A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers

Hereditary Angioedema

United Kingdom
AO GENERIUM

Withdrawn

Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema

Hereditary Angioedema

Russian Federation
KalVista Pharmaceuticals, Ltd.

Completed

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Hereditary Angioedema

United Kingdom
Francis Corazza

Completed

Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome

COVID-19

Belgium
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Multiple Doses of ALXN2050 in Healthy Adults

Healthy

New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Single-dose ALXN2050 in Healthy Adults

Healthy

New Zealand
Jianan Psychiatric Center, Ministry of Health and...
National Cheng Kung University; Taiwan Nurses Association

Completed

A Study of Dose-response Relationship and the Evidence Based Multisensory Stimulation Intervention

Psychotic Disorders | Anxiety | Complementary Therapies | Clinical Trial

Taiwan
Shire

Completed

A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE

Hereditary Angioedema

United States
Shire

Completed

Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

United States, Canada, Jordan
Shire

Completed

Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers

Hereditary Angioedema (HAE)

United States
Shire

Completed

Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

Japan
Shire

Completed

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

Hereditary Angioedema (HAE)

United States, Jordan, Italy

Search clinical trials for: complement dose

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations